Nominated Adviser Status

RNS Number : 0704G

Immupharma PLC

01 November 2018

 

1 November 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

Nominated Adviser Status

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser ("NOMAD"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will be removed from the register of NOMADs with effect from 7am (GMT) on 1 February 2019.

In accordance with AIM Rule 1, the Company is required to appoint a new NOMAD by 1 February 2019, if not, the Exchange will suspend trading in the Company's AIM Securities. If the Company does not appoint a replacement NOMAD by 4 March 2019, the admission of its AIM Securities will be cancelled. 

The Company has commenced the process to appoint a new NOMAD and will make a further announcement in due course.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information please contact: ImmuPharma plc (www.immupharma.co.uk) + 44 (0) 20 7152 4080 Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations  + 44 (0) 7721 413496 Northland Capital Partners Limited (NOMAD & Joint Broker) David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking Stanford Capital Partners (Joint Broker) Patrick Claridge Chris Coleman SI Capital (Joint Broker)                                                                      Nick Emerson [phone] [phone] [phone]

 

END

 

 

MSCUGGQWGUPRGWG